MYCN and neuroblastoma: In silico analysis of the National Cancer Institute’s Therapeutically Applicable Research to Generate Effective Treatment (TARGET) program database (https://ocg.cancer.gov/programs/target) was performed to compare AF1Q, MYCN and NTRK1 gene expression in 249 primary neuroblastoma tumors segregated into three clinical categories: (1) high-risk MYCN amplified; (2) high-risk MYCN non-amplified; (3) low-risk.